Walter K. Kraft
Walter K. Kraft
Professor of Pharmacology and Experimental Therapeutics, Thomas Jefferson University
Verified email at jefferson.edu - Homepage
Title
Cited by
Cited by
Year
Obstructive sleep apnea syndrome and postoperative complications: clinical use of the STOP-BANG questionnaire
TS Vasu, K Doghramji, R Cavallazzi, R Grewal, A Hirani, B Leiby, ...
Archives of Otolaryngology–Head & Neck Surgery 136 (10), 1020-1024, 2010
1862010
Acid peptic diseases: pharmacological approach to treatment
A Mejia, WK Kraft
Expert review of clinical pharmacology 2 (3), 295-314, 2009
1132009
The nephrotoxicity of vancomycin
EJ Filippone, WK Kraft, JL Farber
Clinical Pharmacology & Therapeutics 102 (3), 459-469, 2017
1102017
Diurnal variation of the human adipose transcriptome and the link to metabolic disease
A Loboda, WK Kraft, B Fine, J Joseph, M Nebozhyn, C Zhang, Y He, ...
BMC medical genomics 2 (1), 7, 2009
1032009
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects
RA Blum, A Majumdar, J McCrea, J Busillo, LH Orlowski, D Panebianco, ...
Clinical therapeutics 25 (5), 1407-1419, 2003
1012003
Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial
WK Kraft, E Gibson, K Dysart, VS Damle, JL LaRusso, JS Greenspan, ...
Pediatrics 122 (3), e601-e607, 2008
1002008
Potential for interactions between caspofungin and nelfinavir or rifampin
JA Stone, EM Migoya, L Hickey, GA Winchell, PJ Deutsch, K Ghosh, ...
Antimicrobial agents and chemotherapy 48 (11), 4306-4314, 2004
962004
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects
WK Kraft, PS Chang, MLPS van Iersel, H Waskin, G Krishna, ...
Antimicrobial agents and chemotherapy 58 (7), 4020-4025, 2014
902014
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome
WK Kraft, K Dysart, JS Greenspan, E Gibson, K Kaltenbach, ME Ehrlich
Addiction 106 (3), 574-580, 2011
862011
Buprenorphine for the treatment of the neonatal abstinence syndrome
WK Kraft, SC Adeniyi-Jones, I Chervoneva, JS Greenspan, D Abatemarco, ...
New England Journal of Medicine 376 (24), 2341-2348, 2017
832017
Buprenorphine for the treatment of the neonatal abstinence syndrome
WK Kraft, SC Adeniyi-Jones, I Chervoneva, JS Greenspan, D Abatemarco, ...
New England Journal of Medicine 376 (24), 2341-2348, 2017
832017
The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers
WK Kraft, B Steiger, D Beussink, JN Quiring, N Fitzgerald, HE Greenberg, ...
The Journal of Clinical Pharmacology 44 (1), 67-72, 2004
832004
Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung …
AT HASTIE, WK KRAFT, KB NYCE, JG ZANGRILLI, ALII MUSANI, JE FISH, ...
American journal of respiratory and critical care medicine 165 (2), 266-272, 2002
752002
Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting
DH Kim, C Daskalakis, DJ Whellan, IR Whitman, S Hohmann, ...
The American journal of cardiology 103 (10), 1391-1395, 2009
702009
BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study
R Nettles, C Chien, E Chung, A Persson, M Gao, M Belema, NA Meanwell, ...
Hepatology 48 (suppl 1), 1025A, 2008
652008
Indinavir and rifabutin drug interactions in healthy volunteers
WK Kraft, JB McCrea, GA Winchell, A Carides, R Lowry, EJ Woolf, ...
The Journal of Clinical Pharmacology 44 (3), 305-313, 2004
652004
Single-and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C
C Pasquinelli, F McPhee, T Eley, C Villegas, K Sandy, P Sheridan, ...
Antimicrobial agents and chemotherapy 56 (4), 1838-1844, 2012
552012
Prevalence of obstructive lung disease in HIV population: a cross sectional study
A Hirani, R Cavallazzi, T Vasu, M Pachinburavan, WK Kraft, B Leiby, ...
Respiratory medicine 105 (11), 1655-1661, 2011
542011
MK-0448, a specific Kv1. 5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans
BB Pavri, HE Greenberg, WK Kraft, N Lazarus, JJ Lynch, JJ Salata, ...
Circulation: Arrhythmia and Electrophysiology 5 (6), 1193-1201, 2012
502012
Pharmacologic management of the opioid neonatal abstinence syndrome
WK Kraft, JN van den Anker
Pediatric Clinics 59 (5), 1147-1165, 2012
502012
The system can't perform the operation now. Try again later.
Articles 1–20